Advances in prostaglandin E2 reprogramming pancreatic cancer microenvironment / 上海交通大学学报（医学版）

ABSTRACT

Pancreatic cancer is a highly malignant disease with poor prognosis. Accumulating evidences indicate that prostaglandin E2 (PGE2) can promote cancer progression by reprogramming tumor microenvironment (TME). On one hand, PGE2 can regulate immune cells, tumor cells, cancer-associated fibroblasts and endothelial cells in TME to boost growth, invasion and metastasis of pancreatic cancer. On the other hand, exosomes from tumor cells influence the synthesis, release and uptake of PGE2 and enhance its reprogramming abilities. Furthermore, PGE2 even plays an important role in the development of therapy resistance by stimulating tumor repopulation and inducing epithelial-mesenchymal transition. Hence, PGE2 might be a potential therapeutic target for intervention of pancreatic cancer.